Clinical trial
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone…
NCT00095654 · Gerstein, Hertzel, MD, Other · Completed
Key facts
| NCT number | NCT00095654 |
|---|---|
| Title | The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial |
| Official title | The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial |
| Lead sponsor | Gerstein, Hertzel, MD, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) Aventis Pharmaceuticals Industry GlaxoSmithKline King Pharmaceuticals is now a wholly owned subsidiary of Pfizer Wyeth is now a wholly owned subsidiary of… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Impaired Glucose Tolerance, Cardiovascular Disease, Glucose Metabolism Disorders |
| Intervention type | Drug |
| Interventions | Ramipril, Rosiglitazone |
| Enrollment | 5,000 |
| Start date | Jul 1, 2001 |
| Completion | Oct 1, 2006 |
| First posted | Nov 8, 2004 |
| Last update posted | Nov 10, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: